Table 1.
Molecular, functional characteristics and source of origin of the indicated cell lines
| Sample | Microsatellite status | Altered MSI markers | Genome evolvability | Split ratio | In vitro doubling time | Growth rate | Source |
|---|---|---|---|---|---|---|---|
| C10 | Stable | – | Stable | 0.34 | 2.33 | 0.30 | ECACC |
| C106 | Stable | – | Stable | 0.35 | 2.50 | 0.28 | ECACC |
| C125PM | Stable | – | Stable | 0.34 | 2.37 | 0.29 | ECACC |
| C32 | Stable | – | Stable | 0.18 | 1.54 | 0.45 | ECACC |
| C70 | Stable | – | Stable | 0.4 | 2.76 | 0.25 | ECACC |
| C75 | Stable | – | Stable | 0.36 | 2.46 | 0.28 | ECACC |
| C99 | Stable | – | NA | NA | NA | NA | ECACC |
| CACO2 | Stable | – | Stable | 0.26 | 1.83 | 0.38 | ATCC |
| CAR1 | Stable | – | Stable | 0.36 | 2.47 | 0.28 | JCRB |
| CCK81 | Unstable | bat26-nr21-bat25-mono27-nr24 | Evolving | 0.34 | 2.53 | 0.27 | RIKEN |
| CL14 | Stable | – | NA | NA | NA | NA | DSMZ |
| COCM1 | Stable | – | Evolving | 0.3 | 2.34 | 0.30 | JCRB |
| COGA1 | Unstable | bat26-mono27-nr24 | NA | NA | NA | NA | Dr. Hubera |
| COGA2 | Stable | – | Stable | 0.32 | 2.22 | 0.31 | Dr. Hubera |
| COGA5 | Stable | – | Stable | 0.20 | 1.69 | 0.41 | Dr. Hubera |
| COGA8 | Stable | – | Stable | 0.22 | 1.67 | 0.41 | Dr. Hubera |
| COLO201 | Stable | – | NA | NA | NA | NA | ATCC |
| COLO94H | Stable | – | Stable | 0.45 | 2.81 | 0.25 | CLS |
| DIFI | Stable | – | NA | NA | NA | NA | Dr. Baselgab |
| DLD1 | Unstable | bat26-nr21-bat25-mono27-nr24 | Evolving | 0.07 | 0.98 | 0.71 | NCI60 |
| HCA24 | Stable | – | Evolving | 0.33 | 2.22 | 0.31 | ECACC |
| HCA46 | Stable | – | Stable | 0.4 | 2.41 | 0.29 | ECACC |
| HCC2998 | Stable | – | Stable | 0.34 | 2.33 | 0.30 | NCI60 |
| HDC114 | Stable | – | Evolving | 0.23 | 1.69 | 0.41 | DKFZc |
| HDC142 | Stable | – | Evolving | 0.35 | 2.42 | 0.29 | DKFZc |
| HDC82 | Stable | – | NA | NA | NA | NA | DKFZc |
| HRA16 | Stable | – | NA | NA | NA | NA | ECACC |
| HROC24 | Unstable | bat26-nr21-bat25-mono27-nr24 | Evolving | 0.16 | 1.23 | 0.56 | Dr. Linnebacherd |
| HROC32 | Stable | – | Stable | 0.62 | 6.07 | 0.11 | Dr. Linnebacherd |
| HROC334 | Stable | – | Stable | 0.45 | 2.83 | 0.24 | Dr. Linnebacherd |
| HROC39 | Stable | – | Stable | 0.5 | 3.92 | 0.18 | Dr. Linnebacherd |
| HROC69 | Stable | – | Stable | 0.33 | 2.26 | 0.31 | Dr. Linnebacherd |
| HT115 | Stable | – | Evolving | 0.24 | 1.78 | 0.39 | ECACC |
| HT29 | Stable | – | Stable | 0.16 | 1.38 | 0.50 | NCI60 |
| HT55 | Stable | – | Stable | 0.33 | 2.21 | 0.31 | ECACC |
| LIM1215 | Unstable | bat26-nr21-bat25-mono27-nr24 | Evolving | 0.15 | 1.24 | 0.56 | Dr. Whiteheade |
| LIM2099 | Stable | – | Stable | 0.33 | 2.26 | 0.31 | Dr. Whiteheade |
| LOVO | Unstable | nr21-bat25-mono27-nr24 | NA | NA | NA | NA | ATCC |
| LS180 | Unstable | bat26-nr21-bat25-mono27-nr24 | Evolving | 0.25 | 1.90 | 0.37 | ATCC |
| LS411N | Unstable | bat26-nr21-bat25-mono27-nr24 | Evolving | 0.32 | 2.29 | 0.30 | ATCC |
| MDST8 | Stable | – | Stable | 0.15 | 1.31 | 0.53 | ECACC |
| NCIH716 | Stable | – | NA | NA | NA | NA | ATCC |
| OUMS23 | Stable | – | Stable | 0.26 | 1.70 | 0.41 | JCRB |
| OXCO3 | Stable | – | Stable | 0.23 | 1.76 | 0.39 | Dr. Cerundolof |
| RW7213 | Stable | – | Stable | 0.4 | 2.60 | 0.27 | Dr. Arangog |
| SNU1040 | Unstable | bat26-nr21-bat25-mono27-nr24 | Evolving | 0.54 | 4.14 | 0.17 | KCLB |
| SNU1181 | Stable | – | Stable | 0.62 | 4.65 | 0.15 | KCLB |
| SNU1235 | Stable | – | Evolving | 0.35 | 2.33 | 0.30 | KCLB |
| SNU1411 | Stable | – | Evolving | 0.44 | 2.76 | 0.25 | KCLB |
| SNU1460 | Stable | – | NA | NA | NA | NA | KCLB |
| SNU1684 | Unstable | bat26-nr21-bat25-mono27-nr24 | NA | NA | NA | NA | KCLB |
| SNU175 | Unstable | bat26-nr21-bat25-mono27 | NA | NA | NA | NA | KCLB |
| SNU283 | Stable | – | NA | NA | NA | NA | KCLB |
| SNU479 | Stable | – | NA | NA | NA | NA | KCLB |
| SNU81 | Stable | – | Evolving | 0.42 | 2.33 | 0.30 | KCLB |
| SNU977 | Stable | – | Stable | 0.42 | 2.71 | 0.26 | KCLB |
| SNUC1 | Stable | – | NA | NA | NA | NA | KCLB |
| SW1417 | Stable | – | NA | NA | NA | NA | ATCC |
| SW1463 | Stable | – | NA | NA | NA | NA | ATCC |
| SW480 | Stable | – | Stable | 0.18 | 1.64 | 0.42 | ATCC |
| SW837 | Stable | – | Stable | 0.27 | 2.07 | 0.34 | ATCC |
| V411 | Stable | – | Stable | 0.22 | 1.91 | 0.36 | Dr. Markovitzh |
| V481 | Unstable | bat26-nr21-bat25-mono27-nr24 | NA | NA | NA | NA | Dr. Markovitzh |
| WIDR | Stable | – | NA | NA | NA | NA | Dr. Bernardsi |
Non-commercial cell lines were provided by (a) Dr. L. A. Huber, Cell Biology/Biocenter, Medical University of Innsbruck, Innsbruck, Austria; (b) Dr. Baselga, Chairman & Professor of Medicine, Vall d’Hebron Institute of Oncology (V.H.I.O.), Vall d’ Hebron University Hospital, Barcelona, Spain; (c) Dr. M. Schawb, Division of Tumour Genetics - B030 German Cancer Research Center (DKFZ), Heidelberg, Germany; (d) Dr. M. Linnebacher, Division of Molecular Oncology and Immunotherapy, Department of General Surgery, University of Rostock, Rostock, Germany; (e) Dr. R.H. Whitehead, Depts of Medicine, Cell and Developmental Biology and Cancer Biology, Vanderbilt University, Nashville, USA; (f) Dr. V. Cerundolo, Nuffield Dept of Clinical Medicine, John Radcliffe Hospital, Oxford, UK; (g) Dr. D. Arango, Group of Molecular Oncology, Nanomedicine Research Program, Molecular Biology and Biochemistry Research Center, CIBBIM Nanomedicine, Vall d’Hebron, Barcelona, Spain; (h) Dr. S. Markovitz, Case Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, Case Western Reserve University, Cleveland, USA; (i) Dr. R. Bernards, Division of Molecular Carcinogenesis B7, Netherlands Cancer Institute, Amsterdam, The Netherlands.